Бойкот раку. Защитите себя и своих близких! Советы врача-онколога из Великобритании - Гелена Ариньш

120. Goeptar AR, Koeman JH, van Boekel MAJS, Alink GM. Impact of digestion on the antimutagenic activity of the milk protein casein. Nutr Res 1997; 17: 1363–79.

121. Qin L, Xu J, Wang P, Tong J, Hoshi K. Milk consumption is a risk factor for prostate cancer in Western countries: evidence from cohort studies. Asia Pac J Clin Nutr 2007; 16:467–76.

122. Gao X, LaValley MP, Tucker KL. Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-anlysis. J Natl Cancer Inst 2005; 97: 1768–77.

123. Hamalainen E, Adlercreutz H, Puska P, Pietinen P. Diet and serum sex hormones in healthy men. J Steroid Biochem 1984; 10: 459–64.

124. Hill P, Wynder EL, Garnes H, Walker A. Environmental factors, hormone status, and prostate cancer. Prev Med 1980; 9: 657–66.

125. Ganmaa D, Qin LQ, Wang PY, Tezuka H, Teramoto S, Sato A. A two-generation reproduction study to assess the effects of cows` milk on reproductive development in male and female rats. Fertil Steril 2004; 82: 1106–14.

126. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4: 505–18.

127. Jerome L, Shiry L, Leyland-Jones B. Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions. Endocr Relat Cancer 2003; 10: 561–78.

128. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472–89.

129. Parodi PW. Dairy product consumption and the risk of breast cancer. Intl Dairy J 2009; 19: 551–65.

130. Hoppe C, Molgaard C, Michaelsen KF. Cow`s milk and linear growth in industrialized and developing countries. Annu Rev Nutr 2006; 26: 131–73.

131. Belitz H, Grosch W, Shieberle P 2004. Food chemistry. Berlin, Germany: Springer

132. Fuquay JW, Fox PF, 2011. Encyclopedia of dairy sciences. 2nd ed, vol 1. UK: Academic Press, p 3-60.

133. Slattery ML, Benson J, Berry TD, Duncan D, Edwards SL, Caan BJ, Potter JD. Dietary sugar and colon cancer. Cancer Epidemiolog Biomarkers Prev,1997; 6: 677–85.

134. Larsson SC, Bergkvist L, Wolk A. Consumption of sugar and sugar-sweetened foods and the risk of pancreatic cancer in a prospective study. Am J Clin Nutr 2006; 84:1171–6.

135. Prandini A, Tansini G, Sigolo S, Filippi L, Laporta M, Piva G. On the occurrence of aflatoxin M1 in milk and dairy products. Food Chem Toxicol 2009; 47: 984–91.

136. Turner P, Mendy M, Whittle H, Fortuin M, Hall M, Wild C. Hepatitis B infection and aflatoxin biomarker levels in Gambian children. Trop Med Intl Health 2000; 5: 837–41.

137. Rodriguez MA, Cabrera G, Godeas A. Cyclosporine A from a nonpathogenic Fusarium oxysporum suppressing Sclerotinia sclerotiorum. J Appl Microbiol 2006; 100: 575–586.

138. Pitt J, Wild CP, Baan RA et al. Improving Public Health through Mycotoxin Control 2012; Lyon: IARC (IARC Scientific Publications Series, N 158).

139. World Cancer Report 2014 (p.171).

140. M. Valko, C.J. Rhodes, J. Moncol, M. Izakovic, M. Mazur. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chemico-Biological Interactions 2006; vol 160, issue 1: pp 1–40.

141. G. Unden and J. Bongaert. Alternative respiratory pathways of Escherichia coli: energetics and transcriptional regulation in response to electron acceptors. Biochim et Biophys Acta 1997, 1320, 217–234.

142. Nimptsch K1, Rohrmann S, Kaaks R, Linseisen J. Dietary vitamin K intake in relation to cancer incidence and mortality: results from the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg). Am J Clin Nutr.2010; 91(5): 1348–58.

143. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12: 354–362.

144. Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Gastroenterol 2006; 20: 633–649.

145. Tsugane S, Gey F, Ichinowatari Y, Miyajima Y, Ishibashi T, Matsushima S, Hirota Y, Inami T, Yamaguchi M, Karita K. Cross-sectional epidemiologic study for assessing cancer risks at the population level I. Study design and participation rate. J Epidemiol 1992; 2: 75–81.

146. Tsugane S, Gey F, Ichinowatari Y, Miyajima Y, Ishibashi T, Matsushima S, Hirota Y, Inami T, Yamaguchi M, Karita K. Cross-sectional epidemiologic study for assessing cancer risks at the population level II. Baseline data and correlation analysis. J Epidemiol 1992; 2: 83–89.

147. World Cancer Research Fund, American Institute for Cancer Research Food, Nutrition and Prevention of Cancer: a Global Perspective. Vol 67. Washington DC: American Institute for Cancer Research 1997.

148. Lee SA, Kang D, Shim KN, Choe JW, Hong WS, Choi H. Effect of diet and Helicobacter pylori infection to the risk of early gastric cancer. J Epidemiol 2003; 13: 162–168.

149. IARC. Biological agents. IARC Monogr Eval Carcinog Risks Hum 2012; 100B: 1–441.

150. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001; 49: 347–353.

151. Druesne-Pecollo N; Latino-Martel P; Norat T; Barrandon E; Bertrais S; Galan P; Hercberg S. Beta-carotene supplementation and cancer risk: a systematic review and metaanalysis of randomized controlled trials. International Journal of Cancer 2010; 127 (1): 172–84.

152. Shinya Toyokuni. Role of iron in carcinogenesis: Cancer as a ferrotoxic disease. Cancer Sci. 2009 Jan; 100(1): 9–16.

153. Wu T, Sempos C, Freudenheim J, Muti P, Smit L. Serum iron, copper and zinc concentrations and risk of cancer mortality in US adults. Ann Epidemiol 2004; 14: 195–201.

154. Toyokuni S. Iron-induced carcinogenesis: the role of redox regulation. Radic Biol Med 1996; 20: 553–66.

155. Zacharski L, Ornstein D, Woloshin S, Schwartz L. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J 2000; 140: 98–104.

156. Zacharski L, Chow B, Howes P et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: Results from a randomized trial. J Natl Cancer Inst 2008; 100: 996–1002.